PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-177.89%
Negative net income growth while VET stands at 122.06%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
15.71%
D&A growth well above VET's 6.91%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
68.72%
Some yoy growth while VET is negative at -1060.86%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-8.20%
Negative yoy SBC while VET is 25.11%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-163.27%
Both reduce yoy usage, with VET at -317.08%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-164.71%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-78.79%
Both reduce yoy usage, with VET at -317.08%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-3.45%
Negative yoy while VET is 33.24%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
3.36%
Operating cash flow growth at 50-75% of VET's 6.47%. Martin Whitman would worry about lagging operational liquidity vs. competitor.
-7.61%
Negative yoy CapEx while VET is 31.16%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-96.47%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
7.61%
Purchases growth of 7.61% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-214.29%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-7.61%
Both yoy lines negative, with VET at -153.69%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-406.71%
We reduce yoy invests while VET stands at 17.40%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.